miRNA as a Prognostic Marker in Small Lung Cell Carcinoma

Area of Science:

• Oncology
• Molecular Biology
• Genetics

Background:

• Small-cell lung carcinoma (SCLC) is a highly aggressive malignancy with limited effective biomarkers.
• Current treatments for SCLC face challenges due to rapid progression, metastasis, and relapse.

Purpose of the Study:

• To review the role of microRNAs (miRNAs) in regulating SCLC biology.
• To discuss the potential clinical applications of miRNAs as biomarkers and therapeutic targets in SCLC.

Main Methods:

• A narrative literature review was conducted.
• Searches of PubMed and Scopus databases were performed to identify relevant studies on miRNAs in SCLC.

Main Results:

• Fourteen specific miRNAs (e.g., miR-7-5p, miR-22-3p) were identified as regulators of SCLC progression, metastasis, and therapy resistance.
• These miRNAs influence key signaling pathways like PI3K/Akt, Hippo, and DNA repair.
• Abnormal miRNA expression correlates with patient outcomes and suggests potential for non-invasive monitoring via plasma or exosomes.

Conclusions:

• MicroRNAs are central to SCLC pathogenesis and progression.
• miRNA profiling holds promise for refining SCLC diagnosis, risk assessment, and therapeutic strategies.
• miRNA-based therapeutics (mimics, antagomiRs) may enhance drug sensitivity and complement existing SCLC treatments.